Clinical Trial Update: Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a PreFED diet in combination with ipilimumab and nivolumab for patients with ICB-refractory melanoma. The trial is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: ICB-refractory Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING